VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals names new CFO, boosts shareholder stake, and reinforces its biotech leadership—discover how these moves shape the company’s growth and market outlook.

Vertex outperforms Regeneron with a three‑fold higher ROIC, showcasing superior capital discipline, efficient asset turnover, and a robust precision‑medicine pipeline for sustainable growth.

Vertex Pharmaceuticals: Boston‑based biotech driving breakthrough therapies for cystic fibrosis, cancer, and more, with strong financials and a robust pipeline that keeps investors confident.

Vertex’s Q2 2026 earnings beat expectations, lifting 2026 revenue guidance and highlighting strong CF drug sales, a growing pipeline, and a strategic Crinetics acquisition.

Vertex Pharmaceuticals’ latest earnings show strong growth, a resilient stock, and a commitment to R&D that drives breakthrough biotech innovation.

Vertex Pharmaceuticals’ $485/share surge follows FDA approval of a new CF drug and the acquisition of CRNX, boosting its biotech pipeline and investor confidence.

Vertex’s $10 B takeover of Crinetics expands its portfolio into endocrinology, adding Phase III assets and boosting revenue potential.

Vertex Pharmaceuticals hits a 52‑week high at $529.14, showcasing strong growth and investor confidence while advancing breakthrough treatments in cystic fibrosis and cancer.

Vertex expands CASGEVY gene‑therapy to children as young as two, offering earlier treatment for sickle cell and β‑thalassemia while boosting market reach and investor confidence.

Explore Vertex Pharmaceuticals’ latest breakthroughs in cystic fibrosis and cancer, market trends, and investment insights—discover how the Boston‑based biotech leader shapes global healthcare.